Back

Cardiotoxicity induced by the combinatorial treatment based on the immune checkpoint inhibitor pembrolizumab associated to trastuzumab

1 September 2019 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 2 - Risk Factors and Prevention, Cardiovascular Disease in Special Populations Cardiovascular Risk Assessment ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

29 More presentations in this session

Presentation thumbnail
Doctor S. Harb (Cleveland, US)
Abstract Slides
Presentation thumbnail
Doctor V. Aengevaeren (Nijmegen, NL)
Abstract Slides
Presentation thumbnail
Doctor T. Infante (Naples, IT)
Abstract Slides
Presentation thumbnail
Doctor M. Anguita Sanchez (Cordoba, ES)
Abstract Slides
Presentation thumbnail
Doctor G. Brooks (London, GB)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Risk Factors and Prevention, Cardiovascular Disease in Special Populations

The Event

Event poster

ESC Congress 2019

1 September 2019 08:30 CET
You may be interested in
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
Update on dyslipidaemia management: focus on risk estimation and lipoprotein(a)